Study of Metatinib Tromethamine Tablet

Inclusion Criteria: * Patients with advanced or metastatic gastric cancer or colorectal cancer who progress after second-line therapy or the above treatment protocol, or patients with advanced or metastatic hepatocellular carcinoma who progress after first-line chemotherapy, interventional therapy or targeted therapy shall be verified by histology or cytology; or patients with advanced or metastatic non-squamous non-small cell lung cancer who cannot be operated or fail to first-line therapy shall be verified by histology or cytology; * MET gene amplification or protein overexpression(IHC ≥2+）,or exon-14 skipping; * At least one measurable lesion (RECIST 1.1 ); * At least 4 weeks from the last chemotherapy, radiotherapy or anti-tumor biological products treatment; at least 8 weeks from the last anti-tumor antibody products treatment; at least 6 weeks from the last dose of nitrosourea, mitomycin C or doxorubicin; * At least 4 weeks from major surgery or trauma, and the wound should fully heal; at least 1 week from minor surgery or trauma (i.e. tissue biopsy or fine needle aspiration); * Toxicity from previous treatment has to restore to ≤ grade 1, baseline or irreversible (NCI CTC4.0); * ECOG performance status 0-1; * Life expectancy ≥3 months; * Adequate hematologic function: ANC≥1.5×10\^9 /L, HB≥90g/L(blood transfusion allowed), PLT≥100×10\^9/L; * Adequate hepatic function: ALT≤3×ULN, AST≤3×ULN, TBIL≤2×ULN(patients with liver metastases or liver cancer ALT≤5×ULN, AST≤5×ULN, TBIL≤2×ULN), Child-Pugh score≤7; * Adequate renal function: uric acid\<500μmol/L, creatinine\<1.7mg/dL, proteinuria≤2＋or≤2g/24h , GFR≥60 ml/min/1.73m\^2; * PT-INR/APTT≤1.5×ULN, Serum sodium, potassium, calcium, magnesium levels ≤1×ULN(NCI-CTC 4.0); * Patients signed written informed consent; * Willingness and capability to comply with protocol requirement and well communicate with investigators. Exclusion Criteria: * Severe, uncontrolled medical disorders or active infection, including but not limited to HIV antibody positive, active tuberculosis, HBV DNA copies\>10\^3/ml; * Subjects have known or suspected brain metastases; * Patients must receive other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for palliative local radiation) or traditional Chinese medicine for treatment of cancer during the study; * Previously received other VEGF/VEGFR small-molecule inhibitors or antibodies therapy, including but not limited to Bevacizumab, Ramucirumab, Aflibercept; * Previously received other HGF/c-Met small-molecule inhibitors or antibodies therapy, including but not limited to Crizotinib, Cabozantinib, Volitinib, Capmatinib (INC280), BPI-9016M; * Imaging showed involvement of major blood vessels or nerves by tumor; * Uncontrolled hypertension (systolic blood pressure\>150mmHg and/or diastolic blood pressure\>100mmHg after treatment); * LVEF\<50%; * Apparent heart disease, including congestive heart failure(NYHA III-IV), history of myocardial infarction, or uncontrolled angina within 6 months prior to enrollment; * Arrhythmias need to be treated, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia or ventricular fibrillation; ECG abnormalities confirmed, including QT interval prolongation (males\>450msec, females\>470 msec); * History of hemorrhagic or thrombotic events within 6 months before enrollment, i.e. cerebrovascular accidents(including TIA), pulmonary embolism, spontaneous hemorrhage of tumor; * Patients need surgery within 28 days, or is expected to require surgery within 28 days after the last dose; * Uncontrolled cavity effusion, such as large amount of pleural effusion and ascites; * Gastrointestinal illnesses(i.e., uncontrolled diarrhea or malabsorption) at screening or within 3 months that may affect drug absorption; * History or suspicious signs of gastrointestinal perforation; * Concomitant medications that may affect the drug metabolism (i.e. strong CYP3A4 inhibitors or inducer ); * Pregnant or lactating women; * Subjects of childbearing refused to use medically acceptable methods of contraception until 3 months after the last dose; * Participate in other clinical trials within 4 weeks prior to enrollment; * The investigators consider the patients are not suitable for this trial